Data Sheet (Cat.No.T16751)



Rilapladib

Chemical Properties


CAS No.: 412950-08-4

Formula: C40H38F5N3O3S

Molecular Weight: 735.8

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

| Description | Rilapladib (SB 659032) is a selective inhibitor of Lipoprotein-Associated Phospholipase A2(Lp-PLA2, IC50 = 230 pM) and an antagonist of the platelet activating factor receptor. |
|---------------|--|
| Targets(IC50) | Phospholipase |
| In vitro | Rilapladib reduces the PAF biological activity and levels, thereby reducing Lp-PLA2 biosynthesis and preventing the possible adverse effects of Lp-PLA2 [2]. |

Solubility Information

Solubility DMSO: 78 mg/mL (106 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|-----------|------------|
| 1 mM | 1.3591 mL | 6.7953 mL | 13.5906 mL |
| 5 mM | 0.2718 mL | 1.3591 mL | 2.7181 mL |
| 10 mM | 0.1359 mL | 0.6795 mL | 1.3591 mL |
| 50 mM | 0.0272 mL | 0.1359 mL | 0.2718 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Shaddinger BC, et al. Platelet aggregation unchanged by lipoprotein-associated phospholipase A_2 inhibition: results from an in vitro study and two randomized phase I trials. PLoS One. 2014 Jan 27;9(1):e83094.

Page 1 of 2 www.targetmol.com



Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com